{
  "id": 280292,
  "title": "Starbucks is ending GLP-1 coverage for weight loss as employer costs climb",
  "url": "https://urgent.news/2026/08/07/starbucks-is-ending-glp-1-coverage-for-weight-loss-as-employer-costs",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-07T20:41:28.000Z",
  "source": {
    "name": "Business Insider",
    "slug": "business-insider",
    "url": "https://www.businessinsider.com/starbucks-cuts-glp-1-coverage-weight-loss-costs-climb-2026-8"
  },
  "original_language": "en",
  "account": "Starbucks has announced it will discontinue coverage for GLP-1 drugs prescribed for weight loss as part of its benefits package for eligible employees, effective October. The coffee chain's decision follows a rise in health care spending on these medications. While GLP-1 drugs are primarily used for diabetes treatment, they have gained popularity in the obesity market. Starbucks' health plans currently cover full- and part-time employees working at least 20 hours per week. However, the company's move aligns with a broader trend among employers grappling with rapidly increasing health care costs. GLP-1 drug coverage accounted for 11.4% of corporate employers' total annual claims last year, up from 6.9% in 2023. Some employers, like Bank of America, are continuing to invest heavily in GLP-1 coverage, with CEO Brian Moynihan emphasizing it as an investment in employee health. Other large employers, such as Allina Health, have also stopped covering GLP-1 drugs for weight loss, citing the significant impact on medical premiums.",
  "summary": "Starbucks is set to end coverage for GLP-1 drugs, which are used for weight loss, for its benefits-eligible employees starting in October. This decision comes as GLP-1 drugs have become a significant share of employers' healthcare spending. While Starbucks is pulling back on coverage for weight-loss drugs, some other large employers, such as Bank of America, are investing heavily in the benefit. Bank of America spends over $250 million annually on GLP-1 coverage, which accounts for about 13% of its healthcare budget. The trend of limiting coverage for GLP-1 drugs is part of a broader recalibration of benefits, as soaring costs are prompting employers to limit eligibility.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}